论文部分内容阅读
为了观察干扰素治疗慢性丙型肝炎病毒(HCV)感染的远期疗效并初步探讨影响疗效的困素,我们对采用干扰素治疗的21例慢性丙型肝炎患者进行了连续三年的追踪随访和研究,现将结果报告如下。资料和方法一、病例选择选择1993.8-1994.8间在湖北省襄樊市中心医院和上海仁济医院就诊的21例慢性丙型肝炎患者采用干扰素治疗,这些患者均符合下列条件:(1)抗 HCV 阳性;(2)血清丙氨酸转氨酶(ALT)反复升高,病程超过12个月;(3)血清 HCV RNA 阳性。排除如下患者:(1)合并其他肝炎或其它肝炎病毒感染者,包括甲型(HAV-IgM 阴性),乙型(HBsAg 阴性),戊型(HEV-IgM 阴性)肝炎病毒和巨细胞病毒(MCV-IgM 阴性),EB 病毒
In order to observe the long-term efficacy of interferon in the treatment of chronic hepatitis C virus (HCV) infection and to explore preliminary factors affecting the efficacy, we conducted a follow-up of three consecutive years for 21 chronic hepatitis C patients treated with interferon Research, the results are reported below. Materials and Methods 1. Case Selection Select 21 cases of chronic hepatitis C patients who were treated in Xiangfan Central Hospital of Hubei Province and Renji Hospital of Shanghai from 1993.8 to 1994.8 to choose interferon therapy. All these patients meet the following conditions: (1) Anti-HCV Positive; (2) serum alanine aminotransferase (ALT) repeatedly increased duration of more than 12 months; (3) serum HCV RNA positive. Patients were excluded from the study as follows: (1) Patients with other hepatitis or other hepatitis virus infections, including type A (HAV-IgM negative), type B (HBsAg negative), HEV-IgM negative hepatitis and cytomegalovirus -IgM negative), Epstein-Barr virus